
New Study Finds Occupancy-Based Control and Automation Solutions Cut Office Energy Use and Carbon Emissions by 22%
Key findings include:
Energy Efficiency Gains: Occupancy-based controls allowed the meeting room to remain in a resting state — at a lower temperature setpoint with minimized HVAC, lighting, and plug load use — 76 per cent of the time during business hours, significantly reducing energy consumption.
Energy and Carbon Reduction: Comparing high-occupancy business days to low-occupancy days over a 4-week period, the study observed the lower occupancy days had an average of a 22 per cent reduction in operational energy and carbon in meeting rooms than on higher occupancy days, associated with fan coil, lighting, and plug load use as direct result of occupancy-based controls applied to these rooms.
Cost Savings & ROI: The estimated payback period of two years for implementing the advanced sensoring that enables occupancy controls, is conservative, as the analysis only accounted for room-level energy cost savings. If energy cost savings from other HVAC components such as air handling units were included, the payback period would likely be even shorter.
Indoor Air Quality & Comfort: Despite the application of controls, CO 2 levels, relative humidity (RH), and volatile organic compounds (VOCs) remained within industry-recommended healthy ranges, supporting occupant well-being.
150 Holborn: A Model for Energy-Efficient, Smart Buildings
The research was conducted during January and February 2024 at 150 Holborn in London, a 9-story, 18,500-square-meter (200,000-square-foot) smart office building designed for sustainability and occupant well-being. A technology-first approach equips the building with a modern Building Management System (BMS) EcoStruxure™ Building Advisor, IoT-enabled sensors EcoStruxure™ Connected Room Solutions, and an integrated room booking system via Planon's Integrated Workplace Management System. The facility represented an ideal test case for evaluating the impact of energy conservation measures (ECMs) in a real-world environment.
The study analyzed how real-time occupancy detection could optimize room conditioning, reducing unnecessary energy consumption while maintaining indoor air quality and occupant comfort. The research team intentionally focused on meeting rooms as the unit of measure—spaces common to all office environments—to ensure broad applicability across commercial buildings.
'This study is compelling and demonstrates how simple, smart adjustments to room settings can have a measurable impact on energy efficiency and carbon, without compromising comfort or air quality,' said Jean-Marc Zola, Building Segments President at Schneider Electric. 'These savings are not hypothetical—they are based on real-world data from a fully operational office building.'
A Scalable Blueprint for Smarter Offices
While 150 Holborn showcases a state-of-the-art smart building, the study's findings are widely applicable to both new and existing office spaces, where similar savings can be achieved in any building equipped with a modern BMS and sensor-based occupancy detection. As businesses face growing pressure to reduce their carbon footprint and operational costs, solutions like occupancy-based controls present an accessible, high-impact strategy for commercial buildings. This research reinforces Schneider Electric's commitment to driving smarter, more sustainable buildings—ensuring that energy efficiency and reduced emissions are not just a goal, but a practical, data-driven reality for offices worldwide.
To access the full white paper, visit here.
About Schneider Electric
Schneider's purpose is to create Impact by empowering all to make the most of our energy and resources, bridging progress and sustainability for all. At Schneider, we call this Life Is On.
Our mission is to be the trusted partner in Sustainability and Efficiency.
We are a global industrial technology leader bringing world-leading expertise in electrification, automation and digitalization to smart industries, resilient infrastructure, future-proof data centers, intelligent buildings, and intuitive homes. Anchored by our deep domain expertise, we provide integrated end-to-end lifecycle AI enabled Industrial IoT solutions with connected products, automation, software and services, delivering digital twins to enable profitable growth for our customers.
We are a people company with an ecosystem of 150,000 colleagues and more than a million partners operating in over 100 countries to ensure proximity to our customers and stakeholders. We embrace diversity and inclusion in everything we do, guided by our meaningful purpose of a sustainable future for all.
Hashtags: #SchneiderElectric #LifeIsOn
SOURCE: Schneider Electric
Copyright Business Wire 2025.
PUB: 03/12/2025 11:50 AM/DISC: 03/12/2025 11:50 AM
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
LOUISVILLE, Ky., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso™ (dordaviprone). It is indicated for the treatment of adult and pediatric patients one year of age and older with diffuse midline glioma harboring an H3 K27M-mutation with progressive disease following prior therapy.1 This indication was approved based on five open-label, non-randomized clinical trials conducted in the U.S. (ONC006 [NCT02525692], ONC013 [NCT03295396], ONC014 [NCT03416530], ONC016 [NCT05392374], and ONC018 [NCT03134131]).1 'Onco360 is grateful for the opportunity to add Modeyso™ to our expansive portfolio of cancer and rare disease therapies as the first and only FDA-approved treatment for pediatric and adult patients with diffuse midline glioma,' said Benito Fernandez. 'We are proud and humbled to be part of this innovative treatment in support of patients, caregivers and families impacted by this devastating disease.' Dordaviprone is a protease activator of the mitochondrial caseinolytic protease P (ClpP) and inhibits dopamine D2 receptor (DRD2). In vitro, dordaviprone activates the integrated stress response, induces apoptosis, and alters mitochondrial metabolism, leading to restored histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma.1 The efficacy of Modeyso was evaluated in an integrated efficacy population of 50 adult and pediatric patients with recurrent H3 K27M-mutant diffuse midline glioma enrolled across five open-label, non-randomized clinical trials.1 The primary outcome was overall response rate (ORR) of 22% (95% CI: 12,36). The trial also demonstrated a duration of response of 10.3 months (95% CI: 7.3, 15.2) with 73% maintaining their response for at least six months and 27% for at least 12 months.1 Dordaviprone demonstrated manageable safety and tolerability adverse events. The most common adverse reactions (≥20 %; all causality) experienced with dordaviprone were fatigue, headache, nausea, vomiting, and musculoskeletal pain.1 Please see the full Prescribing Information for Modeyso. About Onco360 Oncology Pharmacy:Onco360 is the nation's largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Media Contact: Benito Fernandez, Chief Commercial References:1Modeyso™ (Dordaviprone) [Package Insert]. Palo Alto, CA. Jazz Pharmaceuticals. in to access your portfolio
Yahoo
8 hours ago
- Yahoo
Ketjen Introduces New Breakthrough Catalyst Technology that Effectively Mitigates the Effects of Iron Poisoning in FCC Units
Commercial trial demonstrates SaFeGuard's™ effectiveness in processing opportunity crudes HOUSTON, August 20, 2025--(BUSINESS WIRE)--Ketjen Corporation, a leader in catalyst and specialty chemicals manufacturing has launched SaFeGuard™, a new catalyst technology designed to address iron (Fe) poisoning in FCC units. In a recent 30-day full commercial trial, SaFeGuard™ demonstrated a 77% improvement in accessibility with a 50% inventory replacement enabling an increase in unit activity, improved bottoms cracking, and ability to process heavy iron-rich feedstocks. Further testing and predictive modeling suggest that a full 100% inventory changeout could yield up to a 130% increase in accessibility delivering additional improvement in performance. SaFeGuard™ delivers a step change in the contaminant Fe and calcium (Ca) tolerance window by minimizing the Eutectic formation, thereby keeping catalyst pores open. This enables higher activity levels and furthers bottoms cracking, ultimately uplifting profit margins. "We've developed a powerful, safe and sustainable solution that addresses iron poisoning and will increase profitability for our customers by allowing for lower-cost feeds and more efficient operations," said Ketjen's Chief Commercial Officer Henri Tausch. "This new technology is the culmination of decades of research aimed at developing industry leading iron and calcium tolerant catalysis and illustrates our commitment to developing innovative solutions that support the evolving needs of our customers." "SaFeGuard™ is a great option for refiners who are taking advantage of opportunity crudes and even bio feeds because it is just as effective in combating additional contaminants including nickel, vanadium, calcium, sodium, and silicon," said David Leach, Vice President and General Manager, FCC at Ketjen. "It can be used to process iron-rich feedstocks including heavy, resid, tight oil and renewable feeds, and it's also great for units facing accessibility limitations because it requires less frequent catalyst replacement." Ketjen's next generation SaFeGuard™ technology is currently available for use by refiners around the globe. Contact us to learn more about how you can unlock the full potential of your FCC unit. About Ketjen Ketjen is a provider of advanced catalyst solutions to leading producers in the petrochemical, refining and specialty chemicals industries. From fluidized catalytic cracking to clean fuels solutions to hydro-processing to organometallics and curatives, Ketjen delivers safe and reliable solutions that increase production performance and business value. A wholly owned subsidiary of Albemarle Corporation (NYSE: ALB), Ketjen Corporation is headquartered in Houston, Texas, and serves global customers through operations in 25 markets. For more information, visit View source version on Contacts Media Contact: Jennifer Albert, MediaRelations@ Sign in to access your portfolio


Business Wire
8 hours ago
- Business Wire
Ketjen Introduces New Breakthrough Catalyst Technology that Effectively Mitigates the Effects of Iron Poisoning in FCC Units
HOUSTON--(BUSINESS WIRE)--Ketjen Corporation, a leader in catalyst and specialty chemicals manufacturing has launched SaFeGuard™, a new catalyst technology designed to address iron (Fe) poisoning in FCC units. In a recent 30-day full commercial trial, SaFeGuard™ demonstrated a 77% improvement in accessibility with a 50% inventory replacement enabling an increase in unit activity, improved bottoms cracking, and ability to process heavy iron-rich feedstocks. Further testing and predictive modeling suggest that a full 100% inventory changeout could yield up to a 130% increase in accessibility delivering additional improvement in performance. SaFeGuard™ delivers a step change in the contaminant Fe and calcium (Ca) tolerance window by minimizing the Eutectic formation, thereby keeping catalyst pores open. This enables higher activity levels and furthers bottoms cracking, ultimately uplifting profit margins. 'We've developed a powerful, safe and sustainable solution that addresses iron poisoning and will increase profitability for our customers by allowing for lower-cost feeds and more efficient operations,' said Ketjen's Chief Commercial Officer Henri Tausch. 'This new technology is the culmination of decades of research aimed at developing industry leading iron and calcium tolerant catalysis and illustrates our commitment to developing innovative solutions that support the evolving needs of our customers.' 'SaFeGuard™ is a great option for refiners who are taking advantage of opportunity crudes and even bio feeds because it is just as effective in combating additional contaminants including nickel, vanadium, calcium, sodium, and silicon,' said David Leach, Vice President and General Manager, FCC at Ketjen. 'It can be used to process iron-rich feedstocks including heavy, resid, tight oil and renewable feeds, and it's also great for units facing accessibility limitations because it requires less frequent catalyst replacement.' Ketjen's next generation SaFeGuard™ technology is currently available for use by refiners around the globe. Contact us to learn more about how you can unlock the full potential of your FCC unit. About Ketjen Ketjen is a provider of advanced catalyst solutions to leading producers in the petrochemical, refining and specialty chemicals industries. From fluidized catalytic cracking to clean fuels solutions to hydro-processing to organometallics and curatives, Ketjen delivers safe and reliable solutions that increase production performance and business value. A wholly owned subsidiary of Albemarle Corporation (NYSE: ALB), Ketjen Corporation is headquartered in Houston, Texas, and serves global customers through operations in 25 markets. For more information, visit